Results 101 to 110 of about 1,610 (149)

Vulvovaginal atrophy – a tale of neglect

Climacteric, 2014
The impact of vulvovaginal atrophy (VVA) on quality of life continues to be underestimated according to an expert review published in this issue of Climacteric1.
Nick, Panay, Anna, Fenton
openaire   +2 more sources

Ospemifene, vulvovaginal atrophy, and breast cancer

Maturitas, 2013
The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and ...
Gregory T, Wurz, Lin H, Soe, Michael W, DeGregorio   +2 more
openaire   +2 more sources

Vulvovaginal atrophy in women after cancer

Climacteric, 2019
The number of women surviving longer after a cancer diagnosis is increasing. This means that more awareness regarding their health is required. This review will focus on vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause, one of the most distressing adverse iatrogenic effects of the menopause, secondary to cancer therapies.
P, Cox, N, Panay
openaire   +2 more sources

Ospemifene in the Treatment of Vulvovaginal Atrophy

Annals of Pharmacotherapy, 2014
Objective: To review the pharmacology, efficacy, and safety of ospemifene in the management of dyspareunia. Data Sources: Literature was sought using PubMed (1966-January 2014) and EMBASE (1973-January 2014). Search terms included ospemifene, FC-1271a, dyspareunia, vulvovaginal atrophy, and vaginal atrophy.
Kylie N, Barnes, Erica F, Pearce, Abigail M, Yancey, Alicia B, Forinash   +3 more
openaire   +2 more sources

Current treatment options for vulvovaginal atrophy

Expert Review of Obstetrics & Gynecology, 2011
Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide.
Rebekah Burich, Michael DeGregorio
openaire   +1 more source

Management of symptomatic vulvovaginal atrophy

Menopause, 2013
To update and expand the previous position statement of The North American Menopause Society (NAMS) on the management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women.NAMS searched PubMed for medical literature on VVA published since their 2007 position statement on the role of local vaginal estrogen for treatment of vaginal atrophy in
openaire   +3 more sources

Prasterone: A Review in Vulvovaginal Atrophy

Drugs & Aging, 2019
Vulvovaginal atrophy (VVA) is a progressive condition commonly seen in postmenopausal women. The cessation of ovarian estrogen secretion and a fall in serum levels of dehydroepiandrosterone (DHEA), the remaining source of estrogens and androgens, are thought to promote the development of VVA in this population. Intravaginal prasterone (Intrarosa®) is a
openaire   +2 more sources

The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause

Menopause, 2020
Abstract Objective: To estimate the impact of vulvovaginal atrophy (VVA) on sexual function in a clinical population of postmenopausal women. Methods: Women 45 to 75 years old and more than 12 months after the last menstruation, who attended menopausal/gynecological ...
Particco M., Djumaeva S., Nappi R. E., Panay N., Palacios S.   +4 more
openaire   +3 more sources

Treatment of Dyspareunia Secondary to Vulvovaginal Atrophy

Nursing for Women's Health, 2014
Declining estrogen levels associated with menopause can result in vulvovaginal atrophy and some degree of dyspareunia for more than half of all women in menopause. In 2013, the U.S. Food and Drug Administration approved ospemifene, a nonhormonal oral medication for the treatment of dyspareunia in menopause.
openaire   +2 more sources

Advances in the treatment of vulvovaginal atrophy

Expert Review of Obstetrics & Gynecology, 2013
Vulvovaginal atrophy is a frequently neglected symptom of menopause. While an estimated 10–40% of women are affected by the progressive symptoms of vaginal dryness, irritation, itching, dysuria and dyspareunia, only a quarter of symptomatic women are believed to seek medical attention. Until recently, treatments for vulvovaginal atrophy were limited to
Jill M Krapf, Zoe R Belkin, Andrew T Goldstein   +2 more
openaire   +1 more source